PMID- 35280727
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220316
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Adjuvant Therapy With PD1/PDL1 Inhibitors for Human Cancers: A Systematic Review 
      and Meta-Analysis.
PG  - 732814
LID - 10.3389/fonc.2022.732814 [doi]
LID - 732814
AB  - BACKGROUND: Immune checkpoint inhibitors (ICIs) have made a breakthrough in the 
      systemic treatment of patients with advanced tumors. However, little is known 
      about their efficacy and safety in adjuvant settings after the resection of solid 
      tumors. METHODS: We performed a meta-analysis on the efficacy and safety of 
      programmed death 1 (PD1)/PD-1 ligand (PDL1) inhibitors in adjuvant therapy after 
      tumor resection using Review Manager 5.3, based on published clinical studies. 
      The outcomes included recurrence-free survival (RFS), disease-free survival 
      (DFS), overall survival (OS), and adverse events (AEs). RESULTS: Eight randomized 
      controlled trials (RCTs) were included in the analysis. The use of PD1/PDL1 
      inhibitors in adjuvant therapy significantly improved RFS (hazard ratio [HR] = 
      0.72; 95% confidence interval [CI] 0.67-0.78, p < 0.00001). However, there was no 
      statistically significant difference in OS between PD1/PDL1 inhibitors and 
      placebo (HR = 0.86; 95% CI 0.74-1.00, p = 0.05). Gender, age, and PDL1 status 
      were independent predictors of RFS with PD1/PDL1 inhibitors. As for the safety 
      analysis results, PD1/PDL1 inhibitors had a higher incidence of fatigue (risk 
      ratio [RR] = 1.22; 95% CI 1.01-1.49, p = 0.04), nausea (RR = 1.47; 95% CI 
      1.11-1.94, p = 0.007), and pruritus (RR = 1.96; 95% CI 1.57-2.44, p < 0.00001). 
      In addition, the incidence of any grade adverse events increased in the PD1/PDL1 
      inhibitor group (RR = 1.03; 95% CI 1.02-1.05, p < 0.0001). CONCLUSIONS: This is 
      the first meta-analysis on the efficacy and safety of PD1/PDL1 inhibitors in 
      adjuvant therapy. The use of PD1/PDL1 inhibitors in adjuvant therapy could 
      significantly reduce the recurrence rate after solid tumor resection. However, 
      the incidence of fatigue, nausea, pruritus, and any grade AEs also increased, 
      which should be monitored with vigilance.
CI  - Copyright (c) 2022 Jin, Wei, Weng, Feng, Xu, Wang, Cui, Chen, Wang and Peng.
FAU - Jin, Yao
AU  - Jin Y
AD  - Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
FAU - Wei, Jiayan
AU  - Wei J
AD  - Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
FAU - Weng, Yiming
AU  - Weng Y
AD  - Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
FAU - Feng, Jia
AU  - Feng J
AD  - Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
FAU - Xu, Zexi
AU  - Xu Z
AD  - Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
FAU - Wang, Peiwei
AU  - Wang P
AD  - Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
FAU - Cui, Xue
AU  - Cui X
AD  - Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
FAU - Chen, Xinyi
AU  - Chen X
AD  - Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
FAU - Wang, Jinsong
AU  - Wang J
AD  - Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
FAU - Peng, Min
AU  - Peng M
AD  - Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
LA  - eng
PT  - Systematic Review
DEP - 20220225
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8913885
OTO - NOTNLM
OT  - PD1
OT  - PDL1
OT  - adjuvant therapy
OT  - human cancers
OT  - immune checkpoint inhibitor
OT  - meta-analysis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/03/15 06:00
MHDA- 2022/03/15 06:01
PMCR- 2022/01/01
CRDT- 2022/03/14 05:13
PHST- 2021/06/29 00:00 [received]
PHST- 2022/02/02 00:00 [accepted]
PHST- 2022/03/14 05:13 [entrez]
PHST- 2022/03/15 06:00 [pubmed]
PHST- 2022/03/15 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.732814 [doi]
PST - epublish
SO  - Front Oncol. 2022 Feb 25;12:732814. doi: 10.3389/fonc.2022.732814. eCollection 
      2022.